Navigation Links
Onyx Pharmaceuticals to Present at the 29th Annual J.P. Morgan Healthcare Conference
Date:1/4/2011

EMERYVILLE, Calif., Jan. 4, 2011 /PRNewswire/ -- Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX) today announced that it will present at the 29th Annual J.P. Morgan Healthcare Conference on Monday, January 10, 2011 at 1:00 p.m. Eastern Time (10:00 a.m. Pacific Time).  

Interested parties may access a live webcast of the presentation on our website at:

http://www.onyx-pharm.com/view.cfm/32/Event-Calendar

It is recommended that listeners log on 15 minutes early in order to register and download any necessary software.  For those unable to participate during the live webcast, a recorded replay of the presentation will be available within 24 hours of the completion of the presentation through January 24, 2011.

About Onyx Pharmaceuticals, Inc.

Onyx Pharmaceuticals, Inc. is a biopharmaceutical company committed to improving the lives of people with cancer. The company, in collaboration with Bayer HealthCare Pharmaceuticals Inc., is developing and marketing Nexavar® (sorafenib) tablets, a small molecule drug that is currently approved for the treatment of liver cancer and advanced kidney cancer. Additionally, Nexavar is being investigated in several ongoing trials in a variety of tumor types. Beyond Nexavar, Onyx has established a development pipeline of anticancer compounds at various stages of clinical testing, including carfilzomib, a selective proteasome inhibitor, that is currently being evaluated in multiple clinical trials for the treatment of patients with relapsed or relapsed/refractory multiple myeloma and solid tumors. ONX 0801, an alpha-folate receptor targeted inhibitor of thymidylate synthase, and ONX 0912, an oral proteasome inhibitor, are currently in Phase 1 testing. For more information about Onyx, visit the company's website at www.onyx-pharm.com.

Nexavar® (sorafenib) tablets is a registered trademark of Bayer HealthCare Pharmaceuticals.


'/>"/>
SOURCE Onyx Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Keryx Biopharmaceuticals to Present at 29th Annual J.P. Morgan Healthcare Conference
2. Pier Pharmaceuticals Names Peter Letendre as Chief Executive Officer, President and Director
3. Optimer Pharmaceuticals to Present at the 29th Annual J.P. Morgan Healthcare Conference
4. Pittsburgh-based BIOSAFE Receives EPA Registration and Enters Into Commercialization Agreement with Union Springs Pharmaceuticals
5. Access Pharmaceuticals Raises $6.0 Million In Registered Direct Offering
6. University of Utah and Navigen Pharmaceuticals Announce a New Government Contract to Advance Slit2N for the Treatment of Hemorrhagic Fever and Anthrax Exposure
7. Onyx Pharmaceuticals Announces Positive Complete Results From Carfilzomib Phase 2b Study
8. AVANIR Pharmaceuticals Announces Proposed Public Offering of Common Stock
9. Keryx Biopharmaceuticals to Present at Lazard Capital Markets 7th Annual Healthcare Conference
10. Oramed Pharmaceuticals Presents Results of its Phase IIb Clinical Trial at the Diabetes Technology Meeting 2010 in Bethesda, MD
11. Anadys Pharmaceuticals to Present at the Lazard Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/11/2016)... , Germany and ... QGEN ; Frankfurt Prime Standard: QIA) today ... Targeted RNA Panels for gene expression profiling, expanding QIAGEN,s ... (NGS). The panels enable researchers to select from over ... changes and discover interactions between genes, cellular phenotypes and ...
(Date:2/11/2016)... 11, 2016  Dovetail Genomics™ LLC today announced that ... for a planned metagenomic genome assembly service. Richard ... genome assembly method in a talk on Friday, February ... Technology conference in Orlando, Fla. ... datasets is difficult. Using its proprietary Chicago ...
(Date:2/11/2016)... (PRWEB) , ... February 11, 2016 , ... ... of its new stem cell treatment clinic in Quito, Ecuador. The new facility ... and trauma applications to patients from around the world. , The new ...
(Date:2/10/2016)... , Feb.10, 2016 ASAE is introducing ... Association Management Companies (AMC) the option of joining or ... annual fee determined by staff size, every employee in ... join ASAE and reap all available member benefits.   ... "Our new organizational membership options will allow organizations of ...
Breaking Biology Technology:
(Date:2/2/2016)... Feb. 2, 2016  Based on its recent ... Sullivan recognizes US-based Intelligent Retinal Imaging Systems (IRIS) ... Award for New Product Innovation. IRIS, a prominent ... North America , is poised to set ... diabetic retinopathy market. The IRIS technology presents superior ...
(Date:1/28/2016)... JOSE, Calif., Jan. 28, 2016 Synaptics (NASDAQ: SYNA ... results for its second quarter ended December 31, 2015. ... second quarter of fiscal 2016 increased 2 percent compared to the ... second quarter of fiscal 2016 was $35.0 million, or $0.93 per ... Non-GAAP net income for the first quarter of fiscal 2016 grew ...
(Date:1/22/2016)... 22, 2016 ... of the  "Global Behavioral Biometric Market ... --> http://www.researchandmarkets.com/research/4lmf2s/global_behavioral ) has announced ... Biometric Market 2016-2020"  report to their ... Markets ( http://www.researchandmarkets.com/research/4lmf2s/global_behavioral ) has announced the ...
Breaking Biology News(10 mins):